Aislinn Antrim, Managing Editor

Recurrent C. diff infections were observed in 16% of patients who received bezlotoxumab, compared with 29% of patients who received standard of care alone.

The 5-year overall survival was 18% in the CPX-351 group compared to 8% in the standard chemotherapy group.

CEL-SCI Corporation plans to file for FDA approval in patients with advanced primary squamous cell carcinoma of the head and neck based on these trial results.

The approval is based on results from the phase 2 KEYNOTE-629 trial, which found an objective response rate of 50% in adults with recurrent, metastatic, or locally advanced cutaneous squamous cell carcinoma.

Drugs to treat type 2 diabetes using SGLT2 inhibitors are relatively new, with FDA approvals only within the last decade.

Although researchers identified 3 agents that increased the risk of herpes zoster among patients with psoriasis, they also found 2 therapies that seemed to decrease the risk.

The clinical benefit rate was observed in 16.7% of patients in the balixafortide arm and in 19.6% of patients in the eribulin monotherapy arm.

Study to evaluate the safety and efficacy of talazoparib, an oral PARP inhibitor, in combination with enzalutamide, an androgen receptor inhibitor.

Researchers found an overall response rate of 29.8% in patients treated with 177Lu-PSMA-617, compared to a 1.7% partial response in the standard of care only arm.

Lenacapavir was granted Breakthrough Therapy Designation in May 2019 and is a potential first-in-class capsid inhibitor for the treatment of HIV-1 infection without overlapping resistance with any currently approved antiretroviral therapy.

Treatments to stimulate the release of eggs increase estrogen hormone production and can act on breast cells, which has created concern that this could turn the cells cancerous.

The results from the first phase 3 SURPASS trials showed promising results with tirzepatide in patients with type 2 diabetes.

Although it is the most common hospital-acquired infection, hospitals are not required to report non-ventilator-associated hospital-acquired pneumonia to the CDC National Healthcare Safety Network.

Investigators found that the therapeutic mechanism for bezlotoxumab, the only FDA-approved anti-TcdB antibody, is sensitive to escaping mutations in some bacterial strains.

Studies show that an increased life expectancy is attributable to growth in gross domestic product, increases in the average years of school, and other social factors.

The small-molecule inhibitors of the SOX 11 oncogene showed promise both as single agents and in combination with ibrutinib.

Improvements in glycemic control were seen as early as 3 months after program implementation and were sustained up to a year with continued program engagement.

Researchers observed improvements in total cholesterol, low-density lipoprotein, triglycerides, and serum gamma glutamyl transferase among patients both with and without diabetes.

Myokine cathepsin B, brain-derived neurotrophic factor, and klotho were all found to be influential in delaying the progression of Alzheimer disease.

Panelists also recommended the use of bezlotoxumab as a co-intervention with standard of care antibiotics in patients with a recurrent C. diff infection within the past 6 months.

Investigators observed improvements in inflammation of the cornea and ocular itching among patients receiving Verkazia in both trials.

Results from the LOTIS-2 and LOTIS-3 trials show durable responses and a manageable toxicity profile among patients with both diffuse large B-cell lymphoma and mantle cell lymphoma treated with loncastuximab tesirine-lpyl (Zynlonta).

Investigators identified 2 subgroups at risk of developing bacterial biofilms: those who have taken a significant amount of medications over their lifetimes and those who have undergone organ transplants.

Patients who received non-opioid prescriptions were more likely to report having no pain in the first week after surgery than those who received opioids and both groups reported equal levels of satisfaction.

Researchers noted decreases in control of blood pressure as well as non¬–high-density lipoprotein cholesterol, both of which are risk factors for diabetes.

Torsemide is an alternative for patients who skip loop diuretic treatment due to concerns of excessive urination, as well as individuals with chronic kidney disease.

Researchers found that men with a family history of prostate cancer reached the screening risk threshold up to 12 years earlier than the general population.

A lower antibody response found in one-fourth of patients taking methotrexate does not necessarily mean that these patients are not protected against COVID-19.

Study results demonstrated consistent benefit across higher and lower-risk patients.

Although the United States has surpassed the milestone of 100 million COVID-19 vaccinations, a study found that reaching 200 million will be significantly more challenging as vaccine hesitancy remains.